Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arvinas Inc (NQ: ARVN ) 26.29 -0.70 (-2.59%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Arvinas Inc < Previous 1 2 Next > Arvinas to Participate in Upcoming Investor Conferences June 03, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress May 23, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) May 16, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High February 06, 2024 Via Investor Brand Network Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress May 09, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update May 07, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas to Present at Upcoming Investor Conferences May 02, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer April 24, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 11, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer March 18, 2024 - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - From Arvinas Inc. Via GlobeNewswire Arvinas to Participate in Upcoming Investor Conferences March 04, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 27, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Announces Chief Financial Officer Transition February 20, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease February 20, 2024 From Arvinas Inc. Via GlobeNewswire Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer February 14, 2024 From CARRICK THERAPEUTICS LIMITED Via GlobeNewswire Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer February 06, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference February 01, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Appoints Jared Freedberg as General Counsel January 16, 2024 Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) From Arvinas Inc. Via GlobeNewswire Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program December 05, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program December 05, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium November 28, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas Announces Oversubscribed $350 Million Private Placement November 27, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 07, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas to Participate in Upcoming Investor Conferences November 02, 2023 From Arvinas Inc. Via GlobeNewswire Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC October 22, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day October 18, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023 October 15, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023 October 15, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas to Participate in Upcoming Investor Conferences September 01, 2023 From Arvinas Inc. Via GlobeNewswire Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 08, 2023 From Arvinas Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.